Advances of hematopoietic stem cell transplantation for patients with myelodysplastic syndromes

VernacularTitle:造血干细胞移植治疗骨髓增生异常综合征的研究进展
Author: Guixin ZHANG ; Sizhou FENG
Publication Type:Journal Article
Keywords: Myelodysplastic syndromes; Hematopoietic stem cell trantsplantation
From: Journal of Leukemia & Lymphoma 2009;18(7):437-440
CountryChina
Language:Chinese
Abstract: Hematopoietic cell transplantation (HSCT) offers the most effective therapy for patients with myclodysplastic syndromes (MDS) who have a human leukocyte antigen (HLA)-matched sibling donors and results have improved progressively over the past decade. For patients without an HLA-matched donor,volunteer unrelated donor(VUD) HSCT, unrelated cord blood allogeneic stem cell transplantation (CBT) and autologous HSCT may be the alternative. In this review the indication of transplantation and the prognostic factors for outcome after HSCT including patient age, timing of transplantation, induction chemotherapy before HSCT, conditioning regimens, source of stem cell were analysed.